Frontiers in drug discovery最新文献_第5页

Targeting proteases and proteolytic processing of unusual N-terminal extensions of Plasmodium proteins: parasite peculiarity 疟原虫特异性的靶向蛋白酶和异常N端延伸的蛋白水解处理

Frontiers in drug discovery Pub Date : 2023-07-13 DOI: 10.3389/fddsv.2023.1223140

Ankita Tehlan, A. Saha, S. Dhar

{"title":"Targeting proteases and proteolytic processing of unusual N-terminal extensions of Plasmodium proteins: parasite peculiarity","authors":"Ankita Tehlan, A. Saha, S. Dhar","doi":"10.3389/fddsv.2023.1223140","DOIUrl":"https://doi.org/10.3389/fddsv.2023.1223140","url":null,"abstract":"More than sesquicentennial years of malarial research, however the unique malarial parasite, Plasmodium still bewilders us with its atypical characteristic features. Elimination strategies, deeper knowledge of the parasite biology and pathways can help combat this global health concern that affects ∼250 million people annually. In this review, we unveil an unusual phenomenon observed in the parasite proteome, N-terminal extensions in proteins and highlight that the proteases that may be involved in their processing events, are potential candidates to target this pathogen. Plasmodium encodes larger proteins as compared to its eukaryotic counterparts with homology regions present in the C-terminus of the protein. In contrast, the function of unusual extensions in the N-terminus remains mostly elusive. This novelty observed in Plasmodium proteins is collated here with a focus on replication proteins. The plausible functions and prevalence of these extensions, despite the reduction in genome size, through the parasite evolution are also mentioned. We hypothesize that these extensions, propagated via the energy consuming cellular processes in the otherwise host-dependent obligate parasite, are beneficial to the parasite in ways that are yet to be explored. Consequently, targeting the proteolytic processing of these proteins and the involved proteases would serve as a new drug development regimen to tackle the emerging resistance in parasites to existing antimalarials.","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45716501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FAIR data management: what does it mean for drug discovery? 公平数据管理:对药物发现意味着什么?

Frontiers in drug discovery Pub Date : 2023-07-12 DOI: 10.3389/fddsv.2023.1226727

Yojana Gadiya, V. Ioannidis, David Henderson, P. Gribbon, P. Rocca-Serra, V. Satagopam, Susanna-Assunta Sansone, Wei Gu

{"title":"FAIR data management: what does it mean for drug discovery?","authors":"Yojana Gadiya, V. Ioannidis, David Henderson, P. Gribbon, P. Rocca-Serra, V. Satagopam, Susanna-Assunta Sansone, Wei Gu","doi":"10.3389/fddsv.2023.1226727","DOIUrl":"https://doi.org/10.3389/fddsv.2023.1226727","url":null,"abstract":"The drug discovery community faces high costs in bringing safe and effective medicines to market, in part due to the rising volume and complexity of data which must be generated during the research and development process. Fully utilising these expensively created experimental and computational data resources has become a key aim of scientists due to the clear imperative to leverage the power of artificial intelligence (AI) and machine learning-based analyses to solve the complex problems inherent in drug discovery. In turn, AI methods heavily rely on the quantity, quality, consistency, and scope of underlying training data. While pre-existing preclinical and clinical data cannot fully replace the need for de novo data generation in a project, having access to relevant historical data represents a valuable asset, as its reuse can reduce the need to perform similar experiments, therefore avoiding a “reinventing the wheel” scenario. Unfortunately, most suitable data resources are often archived within institutes, companies, or individual research groups and hence unavailable to the wider community. Hence, enabling the data to be Findable, Accessible, Interoperable, and Reusable (FAIR) is crucial for the wider community of drug discovery and development scientists to learn from the work performed and utilise the findings to enhance comprehension of their own research outcomes. In this mini-review, we elucidate the utility of FAIR data management across the drug discovery pipeline and assess the impact such FAIR data has made on the drug development process.","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42341615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The tumor suppressor 5A2, a synthetic miR-7-5p mimic, targets oncogenic and metabolic pathways, as revealed by transcriptome-wide analysis 全转录组分析显示，肿瘤抑制因子5A2是一种合成的miR-7-5p模拟物，靶向致癌和代谢途径

Frontiers in drug discovery Pub Date : 2023-07-07 DOI: 10.3389/fddsv.2023.1181637

Marion T. J. van den Bosch, Bryony J. Telford, S. Yahyanejad, Thijs de Gunst, Harm C. den Boer, R. Vos, C. Duurland, R. Biemans, L. Dubois, L. V. van Pinxteren, R. Schaapveld, M. Janicot

{"title":"The tumor suppressor 5A2, a synthetic miR-7-5p mimic, targets oncogenic and metabolic pathways, as revealed by transcriptome-wide analysis","authors":"Marion T. J. van den Bosch, Bryony J. Telford, S. Yahyanejad, Thijs de Gunst, Harm C. den Boer, R. Vos, C. Duurland, R. Biemans, L. Dubois, L. V. van Pinxteren, R. Schaapveld, M. Janicot","doi":"10.3389/fddsv.2023.1181637","DOIUrl":"https://doi.org/10.3389/fddsv.2023.1181637","url":null,"abstract":"As cancer is a multifactorial disease, the multimodal action of microRNAs makes them an attractive tool for novel therapeutic approaches. The tumor suppressive miR-7-5p has been shown to act on many aspects of oncogenesis, including cell proliferation, migration and angiogenesis, by targeting a spectrum of key genes. We developed a synthetic chemically modified miR-7-5p mimic, 5A2, and performed a comprehensive functional characterization in a panel of human cancer cell lines. 5A2 reduced cell proliferation in most cell lines by inducing cell cycle arrest. To enable systemic delivery of 5A2 to tumors, it was formulated in a novel lipid nanoparticle (INT-5A2) and we demonstrated the anti-tumor activity of INT-5A2 in an experimental human liver tumor-bearing mouse model. Next, RNA-sequencing was used to gain more insight into the molecular mechanism of action of 5A2 and demonstrated a broad repression of target mRNAs. Interestingly, Ingenuity Pathway Analysis revealed a new role for 5A2 in metabolic pathways. Validation experiments in vitro showed that 5A2 reduced the expression of key glycolysis and glutaminolysis enzymes, leading to a decrease in glycolysis, lactate secretion and intracellular glutamate availability. Taken together, these data strongly suggest that miR-7-5p/5A2 is a potent tumor suppressor that targets various key cellular pathways across cancer types. Therefore, 5A2 may represent a promising novel treatment strategy in oncology.","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43596813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Yin-yang in drug discovery: rethinking de novo design and development of predictive models 药物发现中的阴阳：重新思考预测模型的从头设计和开发

Frontiers in drug discovery Pub Date : 2023-06-21 DOI: 10.3389/fddsv.2023.1222655

Ana L. Chávez‐Hernández, E. López-López, J. Medina‐Franco

{"title":"Yin-yang in drug discovery: rethinking de novo design and development of predictive models","authors":"Ana L. Chávez‐Hernández, E. López-López, J. Medina‐Franco","doi":"10.3389/fddsv.2023.1222655","DOIUrl":"https://doi.org/10.3389/fddsv.2023.1222655","url":null,"abstract":"Chemical and biological data are the cornerstone of modern drug discovery programs. Finding qualitative yet better quantitative relationships between chemical structures and biological activity has been long pursued in medicinal chemistry and drug discovery. With the rapid increase and deployment of the predictive machine and deep learning methods, as well as the renewed interest in the de novo design of compound libraries to enlarge the medicinally relevant chemical space, the balance between quantity and quality of data are becoming a central point in the discussion of the type of data sets needed. Although there is a general notion that the more data, the better, it is also true that its quality is crucial despite the size of the data itself. Furthermore, the active versus inactive compounds ratio balance is also a major consideration. This review discusses the most common public data sets currently used as benchmarks to develop predictive and classification models used in de novo design. We point out the need to continue disclosing inactive compounds and negative data in peer-reviewed publications and public repositories and promote the balance between the positive (Yang) and negative (Yin) bioactivity data. We emphasize the importance of reconsidering drug discovery initiatives regarding both the utilization and classification of data.","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47887205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MMV006087 is a potent Malaria Box compound against Plasmodium falciparum clinical parasites MMV006087是一种有效的抗恶性疟原虫临床寄生虫的疟疾箱化合物

Frontiers in drug discovery Pub Date : 2023-06-15 DOI: 10.3389/fddsv.2023.1190471

J. Chirawurah, Bridget Adikah, F. Ansah, E. Laryea-Akrong, Harry Danwonno, C. Morang’a, Daniel Dosoo, L. Amenga-Etego, G. Awandare, Y. Aniweh

{"title":"MMV006087 is a potent Malaria Box compound against Plasmodium falciparum clinical parasites","authors":"J. Chirawurah, Bridget Adikah, F. Ansah, E. Laryea-Akrong, Harry Danwonno, C. Morang’a, Daniel Dosoo, L. Amenga-Etego, G. Awandare, Y. Aniweh","doi":"10.3389/fddsv.2023.1190471","DOIUrl":"https://doi.org/10.3389/fddsv.2023.1190471","url":null,"abstract":"The emergence of drug-resistant malaria parasites to artemisinin and its partner drugs highlights the need to increase the arsenal of new antimalarials with novel mechanisms of action. To help achieve this aim, this study tested the potency of three Malaria Box compounds (MMV006087, MMV085203, and MMV008956) against five laboratory strains and twenty clinical isolates of Plasmodium falciparum using optimized in vitro growth inhibitory assays. The results were compared to the response from four standard antimalarials-artesunate, chloroquine, mefloquine, and halofantrine. From the results, MMV006087 was the most potent compound with an average IC50 of 22.13 nM compared to MMV085203 (average IC50 of 137.90 nM) and MMV008956 (average IC50 of 262.30 nM). On average, the laboratory strains were also less susceptible to the three Malaria Box compounds (average IC50 of 162.30 nM) compared to the clinical isolates (average IC50 of 135.40 nM). Additionally, MMV006087 was less potent than artesunate but twice more efficacious than chloroquine against the laboratory strains and clinical isolates. The data from this study validate the potency of MMV006087 and MMV085203 as promising antimalarials worthy of further exploration. This study further substantiates the need to include clinical isolates in antimalarial compound screening activities.","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45937320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses 从严重急性呼吸系统综合征冠状病毒2型大流行中可以吸取的教训及其对被忽视的热带虫媒病毒预防和治疗发展的影响

Frontiers in drug discovery Pub Date : 2023-06-01 DOI: 10.3389/fddsv.2023.1176768

Danilo Rosa-Nunes, Danilo B. M. Lucchi, Robert Andreata-Santos, L. Janini, C. Braconi

{"title":"Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses","authors":"Danilo Rosa-Nunes, Danilo B. M. Lucchi, Robert Andreata-Santos, L. Janini, C. Braconi","doi":"10.3389/fddsv.2023.1176768","DOIUrl":"https://doi.org/10.3389/fddsv.2023.1176768","url":null,"abstract":"In the 21st Century, emergence and re-emergence of infectious diseases is significant and has an increasing importance in global concern of public health. Based on the COVID-19 pandemic and recently reported epidemics, most human pathogens originate in zoonosis. Many of such pathogens are related to viruses that have RNA genomes, which can be presented structurally as a single-strand or double-strand. During the last two decades, a timeline of major RNA viruses emergencies can be exemplified, such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003, influenza A virus (H1N1) pdm09 in 2009, Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, Ebola virus (EBOV) in 2013–2016, Zika virus (ZIKV) in 2015 and the SARS-CoV-2 pdm19 in 2019. Even so, prophylactic or therapeutic drugs are unavailable for many RNA viruses circulating. Nonetheless, the COVID-19 pandemic brought considerable scientific advances in accelerating progress regarding prophylaxis, antiviral and drug development, and novel treatments. Regarding RNA virus diseases for humans, arboviruses play an essential and neglected role, constantly reemerging and affecting almost half of the human population, for which no drug has been licensed. Here we review the consolidated RNA viruses’ emergence and re-emergence in the 21st Century through available data. Then, we explored valuable lessons gained during the SARS-CoV-2 pandemic and focused on potential epidemiologic updates, prophylaxis, available treatments, and viral drug inhibitors. Finally, we explore arbovirus’s significance and the ongoing development of effective vaccines, antiviral drugs, and novel therapeutic approaches as strategies to control these neglected tropical diseases (NTD).","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49066776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug discovery and development: introduction to the general public and patient groups 药物发现和开发:向公众和患者群体介绍

Frontiers in drug discovery Pub Date : 2023-05-24 DOI: 10.3389/fddsv.2023.1201419

Natesh Singh, P. Vayer, Shivalika Tanwar, J. Poyet, K. Tsaioun, B. Villoutreix

{"title":"Drug discovery and development: introduction to the general public and patient groups","authors":"Natesh Singh, P. Vayer, Shivalika Tanwar, J. Poyet, K. Tsaioun, B. Villoutreix","doi":"10.3389/fddsv.2023.1201419","DOIUrl":"https://doi.org/10.3389/fddsv.2023.1201419","url":null,"abstract":"Finding new drugs usually consists of five main stages: 1) a pre-discovery stage in which basic research is performed to try to understand the mechanisms leading to diseases and propose possible targets (e.g., proteins); 2) the drug discovery stage, during which scientists search for molecules (two main large families, small molecules and biologics) or other therapeutic strategies that interfere or cure the investigated disease or at least alleviate the symptoms; 3) the preclinical development stage that focuses on clarifying the mode of action of the drug candidates, investigates potential toxicity, validates efficacy on various in vitro and in vivo models, and starts evaluate formulation; 4) the clinical stage that investigates the drug candidate in humans; 5) the reviewing, approval and post-market monitoring stage during which the drug is approved or not. In practice, finding new treatments is very challenging. Despite advances in the understanding of biological systems and the development of cutting-edge technologies, the process is still long, costly with a high attrition rate. New approaches, such as artificial intelligence and novel in vitro technologies, are being used in an attempt to rationalize R&D and bring new drugs to patients faster, but several obstacles remain. Our hope is that one day, it becomes possible to rapidly design inexpensive, more specific, more effective, non-toxic, and personalized drugs. This is a goal towards which all authors of this article have devoted most of their careers. Graphical Abstract","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41899960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The critical role of mode of action studies in kinetoplastid drug discovery. 作用模式研究在发现新药中的关键作用。

Frontiers in drug discovery Pub Date : 2023-05-10 DOI: 10.3389/fddsv.2023.1185679

Alan H Fairlamb, Susan Wyllie

引用次数: 0

Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy 产生一种有效的抗pd - l1 - cd47双特异性抗体，具有很强的治疗性和安全性，可用于癌症免疫治疗

Frontiers in drug discovery Pub Date : 2023-05-09 DOI: 10.3389/fddsv.2023.1182146

Irene Tang, L. Schwimmer, Shenda Gu, Wei Wei Prior, Hieu Van Tran, Allan Chan, Anna McClain, C. Fraser, Chunyang Sun, M. Si, Guijiang Wang, Yunxia Zhao, Ning Zhang, Jiayu Fu, Mengxin Liu, Chuanzeng Cao, Shihao Chen

{"title":"Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy","authors":"Irene Tang, L. Schwimmer, Shenda Gu, Wei Wei Prior, Hieu Van Tran, Allan Chan, Anna McClain, C. Fraser, Chunyang Sun, M. Si, Guijiang Wang, Yunxia Zhao, Ning Zhang, Jiayu Fu, Mengxin Liu, Chuanzeng Cao, Shihao Chen","doi":"10.3389/fddsv.2023.1182146","DOIUrl":"https://doi.org/10.3389/fddsv.2023.1182146","url":null,"abstract":"Cell surface molecules PD-L1 and CD47 are potent inhibitors of adaptive and innate anti-cancer immunity. We sought to generate a safe, therapeutic, bispecific antibody specifically targeting, and blocking both PD-L1 and CD47 inhibitory activity. Novel anti-PDL-1 and anti-CD47 antibodies with favorable inhibitory activity, were humanized and constructed into a unique bi-specific antibody intended for clinical use. Previous pre-clinical and clinical studies using anti-CD47 antibodies indicated anemia and thrombocytopenia as potential risks. QL401 is a PD-L1 x CD47 bispecific antibody engineered to reduce effect on red blood cells while retaining potent phagocytic activation of macrophages in vitro and delayed tumor growth in vivo. QL401 comprises three functional components: a PD-L1 binding Fab arm, a CD47 binding scFv arm, and a human IgG4 backbone. The PD-L1 binding arm provides both tumor targeting and blocking of PD-1 for reactivating T cells. The CD47 arm blocks the binding of SIRPα, while the IgG4 Fc retains Fc gamma receptor binding to provide a phagocytic signal. In preclinical efficacy studies, QL401 potently blocked SIRPα to promote phagocytosis of tumor cells with sub-nanomolar potency. In vivo efficacy studies in mouse xenograft tumor models showed QL401 to be comparable or superior to PD-L1 or CD47 monoclonal antibodies alone or in combination. In vitro safety evaluation of QL401 showed significantly reduced binding and phagocytosis of red blood cells, in contrast to CD47 monoclonal antibodies. In addition, QL401 did not induce hemagglutination. In non-human primates, QL401 was well tolerated up to 100 mg/kg without reduction of red blood cells or platelets below the normal range. QL401 is presently in a human phase I safety study.","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91355037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial: Development/repurposing of drugs to tackle the multiple variants of SARS-CoV-2 社论：开发/重新调整药物用途以应对严重急性呼吸系统综合征冠状病毒2型的多种变体

Frontiers in drug discovery Pub Date : 2023-02-27 DOI: 10.3389/fddsv.2023.1157688

D. Gambino

{"title":"Editorial: Development/repurposing of drugs to tackle the multiple variants of SARS-CoV-2","authors":"D. Gambino","doi":"10.3389/fddsv.2023.1157688","DOIUrl":"https://doi.org/10.3389/fddsv.2023.1157688","url":null,"abstract":"COVID-19, the severe acute respiratory syndrome caused by Coronavirus (SARS-CoV-2) and identified for the first time in China in 2019, was recognized in 2020 as a global pandemic by the World Health Organization (Wu et al., 2020; WHO, 2023). Although elder people and all those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness, people at any age can become seriously ill or die (WHO, 2023). The efforts of pharmaceutical companies and academia have successfully led to several vaccines against this virus in an unprecedented short period of time. Although vaccines provide protection to healthy people, they could be not effective for immune compromised individuals or those bearing some risky pathological comorbidities. Additionally, mutations could generate viral variants unaffected by currently available vaccines. Therefore, new chemotherapeutic agents are urgently needed for the treatment of SARS-CoV-2 in order to reduce virus dissemination and mortality. Although huge efforts are beingmade since 2020 towards the development of new drugs or the repurposing of already approved drugs to other targets, which would lead to a significant drop in the approval time of these drugs, drugs for the treatment of COVID-19 are not yet a reality (Ashburn and Thor, 2004; Nosengo, 2016; WHO, 2023). At present, there is a clinical need for direct-acting antivirals targeting SARS-CoV-2 to complement existing therapeutic strategies. Accordingly, the aim of this Research Topic of Frontiers in Drug Discovery, Antiinfective Agents, is to collect latest research on the topic focused on:","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45053551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1